STEP-3 Extension Data and What Happened After the Trial Ended

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for STEP-3 Extension Data and What Happened After the Trial Ended

At a glance

| Detail | Value | |---|---| | Trial | STEP-3 (NCT03611582) | | N | 611 randomized (407 semaglutide, 204 placebo) | | Intervention | Semaglutide 2.4 mg subcutaneous weekly + intensive behavioral therapy (IBT) | | Comparator | Placebo + IBT | | Duration | 68 weeks (20-week run-in with low-calorie diet, then 48 weeks continued treatment) | | Primary endpoint | Percent change in body weight from baseline to week 68 | | Key result | -16.0% semaglutide+IBT vs -5.7% placebo+IBT (estimated treatment difference: -10.3 percentage points, p < 0.001) |

Why the extension question matters for STEP-3 specifically

STEP-3 was unique in the STEP program because it layered pharmacotherapy on top of intensive behavioral therapy, including an initial low-calorie diet phase (1,000-1,200 kcal/day for the first 8 weeks). That design choice created a steeper early weight-loss trajectory than STEP-1 or STEP-2. Participants in the semaglutide arm lost roughly 6% of body weight during the low-calorie run-in period before the drug even reached full dose.

The clinical question this raises is straightforward: when you combine two potent interventions and then remove one (the drug), does the behavioral component sustain the result? Or does weight trajectory revert regardless of how intensive the lifestyle program was?

What the original 68-week data showed about trajectory

The primary STEP-3 publication reported weight-loss curves that continued to separate between arms through approximately week 40, then plateaued. This plateau pattern is consistent across GLP-1 receptor agonist trials and reflects a new energy-balance set point rather than treatment failure.

Several trajectory details from the original data deserve attention:

| Timepoint | Semaglutide + IBT | Placebo + IBT | |---|---|---| | Week 8 (end of low-calorie diet) | -6.0% | -5.3% | | Week 20 (full dose reached) | -10.3% | -5.2% | | Week 40 (near plateau) | -15.4% | -5.5% | | Week 68 (primary endpoint) | -16.0% | -5.7% |

The placebo arm's trajectory is telling. Despite receiving the same intensive behavioral therapy, including 30 counseling sessions over 68 weeks, participants on placebo regained most of the weight lost during the low-calorie phase by the trial's end. IBT alone did not hold the early deficit.

The STEP-1 extension: the closest proxy for what happens after stopping

STEP-3 itself did not include a formal off-treatment extension period in its primary publication. The strongest evidence for what happens after semaglutide discontinuation comes from the STEP-1 extension study published in 2022 in Diabetes, Obesity and Metabolism. In that analysis, participants who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight over the following year.

Specific findings from the STEP-1 extension (N = 327 who entered the off-treatment period):

  • Mean weight change from week 68 to week 120: participants regained 11.6 of the 17.3 percentage points lost
  • By week 120, net weight loss from original baseline was only about 5.6%
  • Cardiometabolic improvements (waist circumference, HbA1c, lipids) similarly reversed in proportion to weight regain

HealthRX Durability Framework: Applying STEP-1 Extension Data to STEP-3

Because STEP-3 lacked its own published extension, we can construct a reasonable projection by adjusting the STEP-1 extension findings for STEP-3's baseline and IBT context. This requires acknowledging several structural differences.

Factors suggesting STEP-3 participants might retain more weight loss:

  • The IBT component provided 30 structured counseling visits with a registered dietitian, which could build durable habits
  • Participants had already practiced meal replacement and calorie counting during the run-in, potentially improving dietary self-efficacy
  • The study population was selected for willingness to engage in intensive behavioral work

Factors suggesting similar or worse regain:

  • The STEP-1 extension showed that weight regain occurred even among participants who received standard lifestyle counseling, suggesting behavioral support alone does not prevent biological weight rebound
  • Hunger and appetite scores, which improved on semaglutide, returned to near-baseline levels after drug discontinuation in STEP-1, consistent with the pharmacology of GLP-1 receptor agonism
  • The STEP-5 trial (104 weeks of continuous semaglutide) demonstrated that sustained treatment maintained weight loss at -15.2%, arguing that continued pharmacotherapy is the variable that matters, not the intensity of initial behavioral intervention

Projected STEP-3 off-treatment trajectory (estimated):

| Scenario | Projected net weight loss at 1 year post-discontinuation | |---|---| | Same regain rate as STEP-1 extension (67% regain) | -5.3% from original baseline | | IBT provides 20% additional retention | -7.4% from original baseline | | Complete regain to placebo-arm level | -5.7% (matching IBT-only result) |

The most likely outcome sits near the first scenario. IBT may slow the rate of regain by several months, but the biological drivers of weight recovery (reduced energy expenditure, increased appetite signaling, hormonal adaptation) operate independent of behavioral skill acquisition.

Safety signals across the treatment and post-treatment periods

The STEP-3 safety data at 68 weeks showed the expected GLP-1 side-effect profile, with gastrointestinal events dominating:

| Adverse event | Semaglutide + IBT (%) | Placebo + IBT (%) | |---|---|---| | Nausea | 51.7 | 26.3 | | Diarrhea | 36.7 | 22.7 | | Constipation | 30.0 | 10.6 | | Vomiting | 24.3 | 7.1 | | Discontinuation due to AEs | 3.4 | 0 |

Two safety observations are worth highlighting for the post-treatment context. First, the combination of a low-calorie diet with a GLP-1 agonist during the run-in phase produced a higher nausea rate (51.7%) than STEP-1 (44.2%), suggesting the dual appetite-suppression strategy compounds GI burden without proportional benefit. Second, gallbladder-related events occurred in 2.5% of the semaglutide arm versus 0.5% on placebo, consistent with the known association between rapid weight loss and cholelithiasis flagged in the Wegovy prescribing label.

Post-treatment, the relevant safety concern shifts. Rapid weight regain after GLP-1 discontinuation has been associated in observational data with unfavorable body composition changes. Patients may regain a higher proportion of fat mass relative to lean mass compared to their pre-treatment composition. This "fat overshooting" phenomenon is not unique to pharmacotherapy; it occurs after any rapid weight loss. But the speed and magnitude of semaglutide-induced loss may amplify it.

What STEP-4 taught about interruption and restart

The STEP-4 withdrawal trial provides a more controlled look at the discontinuation question than the STEP-1 extension. In STEP-4, all participants received semaglutide 2.4 mg for 20 weeks. At week 20, they were randomized to continue semaglutide or switch to placebo for an additional 48 weeks.

Results were unambiguous:

  • Continued semaglutide: additional -7.9% weight loss (total -17.4% from baseline)
  • Switched to placebo: +6.9% weight regain (net -5.0% from baseline by week 68)

This confirms that the pharmacological effect accounts for most of the weight-loss maintenance. The behavioral and dietary changes that patients adopt while on treatment, even when reinforced by IBT as in STEP-3, do not independently prevent regain once the drug's appetite and satiety effects are removed.

The clinical translation problem

For clinicians and patients interpreting STEP-3, the extension and follow-up data from the broader program create a clear framework for decision-making:

Starting semaglutide with IBT is not a "course of treatment." Unlike antibiotics or acute interventions, obesity pharmacotherapy with GLP-1 agonists functions as chronic disease management. STEP-3's impressive 16.0% weight loss required ongoing drug exposure. The 2023 American Gastroenterological Association guidelines explicitly recommend anti-obesity medications as long-term therapy, not time-limited courses.

IBT adds value during treatment but does not substitute for continued pharmacotherapy. STEP-3 showed that semaglutide plus IBT produced modestly greater weight loss than semaglutide plus standard counseling in STEP-1 (16.0% vs 14.9%). The difference is clinically meaningful for some patients but does not change the discontinuation calculus.

Insurance and access implications are substantial. If long-term treatment is required for weight maintenance, the cost structure of semaglutide (list price approximately $1,300-1,400/month for Wegovy) becomes the primary barrier. STEP-3's results, while impressive, must be read alongside the reality that most patients will face treatment interruptions driven by formulary changes, prior authorization failures, or out-of-pocket cost burden.

Limitations of the available follow-up evidence

Several gaps remain in our understanding of STEP-3's long-term implications:

  1. No published STEP-3-specific extension data. All post-treatment projections rely on extrapolation from STEP-1 and STEP-4, which used different behavioral support intensities.
  2. Body composition data are limited. STEP-3 reported waist circumference but not DEXA or BIA lean mass measurements. The quality of weight lost and regained remains uncertain.
  3. The trial population was 75% female and 83% White, limiting generalizability. Follow-up data from more diverse populations are needed.
  4. Duration of IBT after drug discontinuation was not studied. Whether continuing IBT sessions during a drug washout period would slow regain is an open question with no trial data.
  5. Cardiovascular outcome data from the STEP-3 population do not exist. The SELECT trial demonstrated cardiovascular benefit for semaglutide 2.4 mg in patients with established CVD, but STEP-3 enrolled a general obesity population without requiring cardiovascular disease at baseline.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  • Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed
  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
  • Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. PubMed
  • Wegovy (semaglutide) prescribing information. FDA. Label
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
  • American Gastroenterological Association guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2023;164(2):218-238. PubMed